Pfizer has been removed from a wide-ranging antitrust lawsuit alleging price-fixing in the U.S. generic drug industry, after a federal judge ruled that state attorneys general failed to establish the company’s involvement in an alleged scheme affecting several medicines.
According to Reuters, which first reported the decision on June 24, U.S. District Judge Michael Shea in Connecticut dismissed Pfizer from a lawsuit brought by 45 states, the District of Columbia, and four U.S. territories. The case accuses dozens of pharmaceutical companies and executives of coordinating prices and market behavior for generic medicines, leading consumers and government healthcare programs to pay more for prescription drugs.
The ruling centered on allegations involving Pfizer’s former generic-drug subsidiary, Greenstone, and its role in the market for six generic medicines between 2010 and 2014. Plaintiffs claimed Greenstone participated in arrangements with competitors that included bid-rigging and customer allocation practices, conduct that would violate U.S. antitrust laws if proven. Reuters reported that the states pointed to extensive communications between Greenstone executives and representatives of Sandoz, a major generic drug manufacturer, as evidence of potential coordination.
However, Judge Shea concluded that the evidence was insufficient to hold Pfizer liable. The court found no basis for determining that Pfizer itself participated in a conspiracy, knowingly approved collusive conduct, or could be held responsible under a theory that Greenstone acted solely as its agent. Reuters reported that the judge rejected arguments that Greenstone existed only to serve Pfizer’s interests, noting that the subsidiary operated as a profit-generating generic drug business.
The medications at issue included generic versions of treatments used for conditions such as high blood pressure, glaucoma, and acne, according to Reuters.
States Continue Pursuit of Broader Case
The dismissal affects only Pfizer’s role in one portion of a much larger litigation effort targeting the generic pharmaceutical industry.
Read more: UK Appeals Court Overturns Tribunal Decision in Long-Running Pfizer-Flynn Antitrust Case
The broader lawsuit remains one of the most significant antitrust actions ever brought against generic drug manufacturers. State attorneys general allege that dozens of companies coordinated prices across approximately 80 generic medications, many of them commonly prescribed products. Reuters previously reported that Judge Shea allowed most of the states’ claims against other defendants to proceed in 2025, rejecting efforts to dismiss the case on procedural grounds.
Connecticut Attorney General William Tong, who has played a leading role in the litigation, said state officials are reviewing the latest ruling. In a statement reported by Reuters, Tong said the states remain committed to pursuing claims against the remaining defendants and argued that stronger competition is necessary to reduce prescription drug costs.
New York Attorney General Letitia James’ office, which opposed Pfizer’s dismissal request, declined to comment, Reuters reported.
Antitrust Scrutiny of the Pharmaceutical Industry
The case highlights continuing regulatory and legal scrutiny of competition within pharmaceutical markets, particularly the generic-drug sector. Generic medicines are intended to provide lower-cost alternatives after brand-name drug patents expire, making competitive pricing a central issue for healthcare systems and consumers.
Federal and state authorities have spent years investigating allegations that certain manufacturers coordinated pricing rather than competing independently. Several related cases involving generic-drug pricing remain active in federal courts, while some companies have entered settlements in separate litigation without admitting wrongdoing.
Competition concerns in healthcare have drawn increasing attention from regulators and lawmakers, who argue that market concentration and anticompetitive conduct can contribute to higher drug costs. Antitrust enforcement agencies have repeatedly identified pharmaceutical markets as an area requiring close oversight because of their importance to public health spending and consumer welfare.
Pfizer’s Response and Remaining Litigation
Pfizer welcomed the court’s decision. Reuters reported that the company described Greenstone as a long-standing supplier of affordable generic medicines and said it would continue defending itself against related claims.
Greenstone was separated from Pfizer in 2020 as part of a transaction that helped create Viatris, a global generic-drug company.
Source: Reuters
